BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment...

BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option

Fresh capital injection strengthens BriaCell's position with $13.8M raise at $4.50 per unit. Full underwriter option signals strong institutional confidence. See terms.

BriaCell's Bria-OTS shows sustained success against breast cancer

BriaCell Therapeutics (TSX:BCT), a Canadian biotechnology stock developing cancer immunotherapies, announced the resolution of the lung metastasis first reported in February in a 78-year-old woman with metastatic breast cancer The achievement comes two months after the patient enrolled in the ongoing phase 1/2 study of Bria-OTS, the company’s personalized off-the-shelf cancer immunotherapy BriaCell stock is up by 23.56 per cent on the news tradi…